These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27665573)

  • 21. Etravirine: new drug. Multidrug-resistant HIV: another option.
    Prescrire Int; 2009 Jun; 18(101):102-3. PubMed ID: 19637414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
    Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
    HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.
    Naccarato M; Yoong D; Kovacs C; Gough K
    Antivir Ther; 2012; 17(3):589-92. PubMed ID: 22293514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplification of antiretroviral therapy with etravirine.
    Martínez E; Nelson M
    AIDS Rev; 2010; 12(1):52-9. PubMed ID: 20216910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multigene and Drug Interaction Approach for Tamoxifen Metabolite Patterns Reveals Possible Involvement of CYP2C9, CYP2C19, and ABCB1.
    Powers JL; Buys SS; Fletcher D; Melis R; Johnson-Davis KL; Lyon E; Malmberg EM; McMillin GA
    J Clin Pharmacol; 2016 Dec; 56(12):1570-1581. PubMed ID: 27198207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
    Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
    Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacokinetics and pharmacodynamics of etravirine.
    Schöller-Gyüre M; Kakuda TN; Raoof A; De Smedt G; Hoetelmans RM
    Clin Pharmacokinet; 2009; 48(9):561-74. PubMed ID: 19725591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
    Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
    Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.
    Song C; Li X; Mao P; Song W; Liu L; Zhang Y
    Eur J Hosp Pharm; 2022 Jul; 29(4):198-201. PubMed ID: 32868386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjects.
    Kang P; Cho CK; Jang CG; Lee SY; Lee YJ; Choi CI; Bae JW
    Arch Pharm Res; 2023 May; 46(5):438-447. PubMed ID: 37097441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.
    Quignot N; Więcek W; Lautz L; Dorne JL; Amzal B
    Toxicol Lett; 2021 Feb; 337():111-120. PubMed ID: 33232775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
    Dailly E; Allavena C; Bouquié R; Deslandes G; Raffi F; Jolliet P
    AIDS Res Hum Retroviruses; 2013 Jan; 29(1):42-6. PubMed ID: 23148588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.
    Schöller-Gyüre M; Kakuda TN; De Smedt G; Vanaken H; Bouche MP; Peeters M; Woodfall B; Hoetelmans RM
    Br J Clin Pharmacol; 2008 Oct; 66(4):508-16. PubMed ID: 18492125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
    Jullien V; Tréluyer JM; Rey E; Jaffray P; Krivine A; Moachon L; Lillo-Le Louet A; Lescoat A; Dupin N; Salmon D; Pons G; Urien S
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3361-6. PubMed ID: 16048948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
    Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM;
    Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
    AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects.
    Lu S; Nand RA; Yang JS; Chen G; Gross AS
    Eur J Clin Pharmacol; 2018 Mar; 74(3):285-296. PubMed ID: 29181698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
    Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.